Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Bevacizumab: a new way of doing business. Part 2.

× No keyword cloud information.

7 in total

1. What is stopping the NHS from using bevacizumab for macular degeneration and other retinal disorders?

Authors: Andrew Lotery; Carrie MacEwen
Journal: BMJ Date: 2014-11-18

2. Surveillance of sight loss due to delay in ophthalmic treatment or review: frequency, cause and outcome.

Authors: B Foot; C MacEwen
Journal: Eye (Lond) Date: 2017-01-27 Impact factor: 3.775

3. Implications for pharmaceutical companies and clinicians from the Bayer v NHS judgement: an increasing budgetary focus for both.

Authors: Hanna I Hyry; Jonathan C P Roos
Journal: Eye (Lond) Date: 2018-11-29 Impact factor: 3.775

4. Licence to save: a UK survey of anti-VEGF use for the eye in 2015.

Authors: A K Shalaby; K Lewis; K Bush; P R Meredith; S Di Simplicio; A J Lockwood
Journal: Eye (Lond) Date: 2016-08-12 Impact factor: 3.775

5. Second-year visual acuity outcomes of nAMD patients treated with aflibercept: data analysis from the UK Aflibercept Users Group.

Authors: H Almuhtaseb; R L Johnston; J S Talks; A J Lotery
Journal: Eye (Lond) Date: 2017-06-16 Impact factor: 3.775

6. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial.

Authors: Usha Chakravarthy; Simon P Harding; Chris A Rogers; Susan M Downes; Andrew J Lotery; Lucy A Culliford; Barnaby C Reeves
Journal: Lancet Date: 2013-07-19 Impact factor: 79.321

7. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol.

Authors: Karina Berg; Terje R Pedersen; Leiv Sandvik; Ragnheiður Bragadóttir
Journal: Ophthalmology Date: 2014-09-13 Impact factor: 12.079

7 in total